Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,520,000 shares, a growth of 23.6% from the November 30th total of 1,230,000 shares. Approximately 4.6% of the shares of the company are short sold. Based on an average trading volume of 744,600 shares, the short-interest ratio is currently 2.0 days.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock traded down $0.03 during midday trading on Tuesday, reaching $1.45. 205,872 shares of the stock were exchanged, compared to its average volume of 379,897. Werewolf Therapeutics has a 52 week low of $1.38 and a 52 week high of $8.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The firm has a market cap of $64.62 million, a PE ratio of -0.95 and a beta of 0.30. The company’s fifty day moving average is $2.04 and its 200-day moving average is $2.20.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in HOWL. Millennium Management LLC increased its stake in Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after acquiring an additional 544,881 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after purchasing an additional 86,800 shares during the last quarter. Walleye Capital LLC raised its stake in Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after purchasing an additional 10,528 shares in the last quarter. SG Americas Securities LLC bought a new stake in Werewolf Therapeutics during the third quarter valued at approximately $29,000. Finally, Rhumbline Advisers bought a new stake in Werewolf Therapeutics during the second quarter valued at approximately $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.